Psychedelic Weekly Headlines | October 7

October 7, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Numinus Wellness ($NUMI | $NUMIF) developed a psilocybin-containing tea bag for use in clinical research. The tea bag will be studied in a Phase I trial of practitioners receiving experiential training for psilocybin-assisted therapy. Press Release

MindMed ($MNMD | $MMED) initiated a Phase I trial to compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and MDMA in healthy subjects. The trial is being conducted at University Hospital Basel Press Release

Tryp Therapeutics ($TRYP | $TRYPF) announced that the World Intellectual Property Organization published their international patent application covering the intravenous administration of psilocybin and psilocin. Press Release

PharmaTher Holdings ($PHRM | $PHRRF) announced grant of U.S. patent covering ketamine for parkinson’s disease. Following their successful Phase I/II clinical study, Pharmather is planning a Phase III study to allow for FDA approval of ketamine for Parkinson’s disease. Press Release

Revitalist Lifestyle And Wellness ($CALM | $RVLWF) and Wake Network partnered with former U.S. Special Operations Command Sergeant Tom Satterly to address Veteran mental health. Revitalist and Wake Network will work with Tom to provide national and international access to ketamine infusions, psychedelic therapies, psychotherapy, and mental health coaching. Press Release

Wellbeing Digital Sciences ($MEDI | $KONEF) entered into an agreement to manage three additional clinics. The clinics will provide IV Ketamine therapy, clinical trial management and site support for psychedelic medicines. Press Release

PharmAla Biotech ($MDMA) has been selected as the MDMA manufacturing partner for a human MDMA trial at a campus of the University of California. This is the first US-based Clinical Trial to utilize PharmAla's MDMA. Press Release

Irwin Naturals ($IWIN | $IWINF) reached a binding agreement to acquire Ketamine Infusions of Idaho. The clinic will join Irwin Naturals Emergence national chain of psychedelic mental-health clinics, which has a total of 11 clinics across six different states. Press Release


Media

CBC: Alberta to be 1st province to regulate psychedelics for therapy, government says

Forbes: Billionaire Bob Parsons: GoDaddy Founder Bets On Psychedelics For Trauma Healing (Video)

BBC: Psychedelics: A Neuroscientist's Guide To How They Change Your Brain

NPR: A Drug Based On Psychedelic LSD Relieves Anxiety And Depression In Mice


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.